摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-chloro-benzene-1,3,5-triyltriamine | 360779-08-4

中文名称
——
中文别名
——
英文名称
2-chloro-benzene-1,3,5-triyltriamine
英文别名
2-Chlor-benzen-1,3,5-triyltriamin;2-Chlor-1.3.5-triamino-benzol;2-chloro-1,3,5-triaminobenzene;2-chlorobenzene-1,3,5-triamine
2-chloro-benzene-1,3,5-triyltriamine化学式
CAS
360779-08-4
化学式
C6H8ClN3
mdl
——
分子量
157.603
InChiKey
USRUADMTSBLIML-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    93.2-94.3 °C
  • 沸点:
    373.4±37.0 °C(Predicted)
  • 密度:
    1.456±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    78.1
  • 氢给体数:
    3
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Functional radiographic imaging methods and agents
    申请人:——
    公开号:US20010031035A1
    公开(公告)日:2001-10-18
    Systems and methods for radiographic imaging of tissue using a radio-opaque imaging agent that in one embodiment accumulates intracellularly in tissue in proportion to its functional, or physiological, activity. In one embodiment, the imaging agent is a cell membrane-permeable, radio-opaque, high affinity ligand for an intracellular target. The imaging agent is administered to a patient, and after an accumulation interval, radiographic images are acquired. The imaging agent preferentially accumulates in certain types of tissue and increases its radio-opacity. The tissue being examined is transilluminated by X-ray beams with preselected different mean energy spectra, and a separate radiographic image is acquired during transillumination by each beam. An image processing system may perform a weighted combination of the acquired images to produce a single displayed image. The system and method thus provides a functional image displayed with the anatomical detail and spatial resolution of a radiographic image. Functional and anatomical information are displayed in complete registration, facilitating localization of abnormal tissue in relation to nearby anatomical structures.
    一种放射性不透明成像剂的系统和方法,其中在一种实施例中,该成像剂在组织内以其功能或生理活性成比例地积累于细胞内。在一种实施例中,该成像剂是一种细胞膜可渗透、放射性不透明、对细胞内靶点具有高亲和力的配体。该成像剂被注入到患者体内,在积累时间间隔之后,进行放射性成像。该成像剂优先积累在某些类型的组织中并增加其放射性不透明度。所检查的组织通过预选不同平均能量谱的X射线束进行透照,并在每个束透照期间获取单独的放射性成像。图像处理系统可以对所获取的图像进行加权组合以生成单个显示图像。因此,该系统和方法提供了一个具有放射性成像图像的解剖细节和空间分辨率的功能图像。功能和解剖信息以完全对准的方式显示,有助于定位异常组织与附近解剖结构的关系。
  • Radiographic assessment of tissue response to compounds
    申请人:——
    公开号:US20010038682A1
    公开(公告)日:2001-11-08
    Radiographic system and method for noninvasively assessing the response of tissue to a compound, such as a therapeutic compound, in vivo. In one embodiment, a non-radioactive, radio-opaque imaging agent accumulates in tissue in proportion to the tissue concentration of a predefined cellular target. The imaging agent is administered to a live organism, and after an accumulation interval, radiographic images are acquired. The tissue being examined is transilluminated by X-ray beams with preselected different mean energy spectra, and a separate radiographic image is acquired during transillumination by each beam. An image processing system performs a weighted combination of the acquired images to produce a first image. The image processing procedure isolates the radiographic density contributed solely by differential tissue accumulation of the imaging agent. A compound is administered to the organism, and after a selected interval, a second radiographic image of the tissue is acquired. Radiographic density contributed by accumulated imaging agent in corresponding areas of tissue in the first and second images are compared. Differences in radiographic density between the images reflect changes in the concentration of the cellular target that have occurred after administration of the compound. The system and method may be used to assess therapeutic efficacy of compounds in the drug discovery process, in clinical trials, and in the evaluation of clinical treatment. In other embodiments, pharmacological and toxicological effects of a wide variety of compounds on tissue in vivo may be noninvasively assessed.
    一种无创评估组织对化合物(如治疗化合物)反应的放射性系统和方法。在一种实施例中,一种非放射性、放射性不透明成像剂在组织中积累,其积累量与预定义的细胞靶点的组织浓度成比例。该成像剂被注入到活体生物中,在积累间隔后,获取放射性图像。正在检查的组织通过预选的不同平均能量谱的X射线束进行透光,并在每个束透光期间获取单独的放射性图像。图像处理系统执行获取的图像的加权组合以产生第一张图像。图像处理过程仅隔离由成像剂的差异组织积累贡献的放射性密度。将化合物注入生物体后,在选择的时间间隔后,获得组织的第二张放射性图像。比较第一张和第二张图像中相应区域的成像剂积累贡献的放射性密度。图像之间的放射性密度差异反映了化合物注入后细胞靶点浓度发生的变化。该系统和方法可用于评估药物发现过程中化合物的治疗效果,在临床试验中以及评估临床治疗中使用。在其他实施例中,可以无创评估广泛的化合物对活体组织的药理和毒理效应。
  • Radiographic assessment of tissue after exposure to a compound
    申请人:——
    公开号:US20020039401A1
    公开(公告)日:2002-04-04
    Radiographic system and method for noninvasively assessing the response of tissue to a compound, such as a therapeutic compound. In one embodiment, a non-radioactive, radio-opaque imaging agent accumulates in tissue in proportion to the tissue concentration of a predefined cellular target. The imaging agent is administered to a live organism, and after an accumulation interval, radiographic images are acquired. The tissue being examined is transilluminated by X-ray beams with preselected different mean energy spectra, and a separate radiographic image is acquired during transillumination by each beam. An image processing system performs a weighted combination of the acquired images to produce a first image. The image processing procedure isolates the radiographic density contributed solely by differential tissue accumulation of the imaging agent. A compound is administered to the organism, and after a selected interval, a second radiographic image of the tissue is acquired. Radiographic density contributed by accumulated imaging agent in corresponding areas of tissue in the first and second images are compared. Differences in radiographic density between the images reflect changes in the concentration of the cellular target that have occurred after administration of the compound. The system and method may be used to assess therapeutic efficacy of compounds in the drug discovery process, in clinical trials, and in the evaluation of clinical treatment. In other embodiments, pharmacological and toxicological effects of a wide variety of compounds on tissue may be noninvasively assessed.
    一种放射性成像系统和方法,用于非侵入性地评估组织对化合物(如治疗性化合物)的反应。在一种实施例中,一种非放射性、放射性不透明成像剂在组织中积累,其积累量与预定义的细胞靶点的组织浓度成比例。将成像剂注入到活体生物中,在积累时间间隔后,获取放射性图像。使用预选的不同平均能量谱的X射线束透过要检查的组织,每束光线透过时获取一张单独的放射性图像。图像处理系统对获取的图像进行加权组合,生成第一张图像。图像处理过程仅隔离成像剂差异组织积累所贡献的放射性密度。将化合物注入生物体中,在选择的时间间隔后,获取组织的第二张放射性图像。比较第一和第二张图像中相应区域的成像剂积累所贡献的放射性密度。图像之间的放射性密度差异反映了化合物注入后细胞靶点浓度发生的变化。该系统和方法可用于评估药物发现过程中化合物的治疗效果,在临床试验和临床治疗评估中使用。在其他实施例中,可以非侵入性地评估各种化合物对组织的药理和毒理效应。
  • RADIOGRAPHIC ASSESSMENT OF TISSUE RESPONSE TO COMPOUNDS
    申请人:Veritas Pharmaceuticals
    公开号:EP1263324B1
    公开(公告)日:2009-12-02
  • FUNCTIONAL RADIOGRAPHIC IMAGING METHODS AND AGENTS
    申请人:Veritas Pharmaceuticals
    公开号:EP1263478A2
    公开(公告)日:2002-12-11
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫